These observations complicate the development of anti-aging drugs targeting the mTOR and IIS pathways. Inhibition of the IIS pathway activates the transcription factor FoxO, and many of the click here lifespan extending effects of IIS inhibition are indeed mediated by FoxO [59]. FoxO also acts as a tumor

suppressor [60 and 61]. Interestingly, a recent study in mammalian cells and C. elegans demonstrated that FoxO/DAF-16 activates expression of glutamine synthetase (GS) and increased GS expression in turn inhibits TORC1 activity [ 62]. In agreement with this finding, another recent report demonstrated that glutaminolysis (the de-amination of glutamine to form α-ketoglutarate) activates mTORC1 [ 63••]. Furthermore, in flies and mammals FoxO blocks TORC1 signaling by inducing expression of sestrins which leads to activation of AMPK,

a negative regulator of TORC1 signaling [ 64, 65 and 66]. In worms, DAF-16 negatively regulates buy Alisertib raptor/daf-15 transcription [ 67]. These findings suggest that FoxO may exert some of its positive effects on lifespan and tumor suppression via inhibition of TORC1 signaling. mTOR signaling is found in all tissues, but is probably particularly important in metabolic tissues. Metabolic organs, such as the liver, muscle and adipose tissue, are particularly sensitive to nutrients, insulin/IGF-1, and energy — the three inputs that control mTOR. Liver, muscle and adipose tissue, in turn, control whole body glucose and lipid homeostasis. Below we review recent studies on the regulation of glucose and lipid homeostasis by mTOR in metabolic tissues. Upon fasting, the liver produces glucose via glycogen breakdown (glycogenolysis) or via glucose synthesis (gluconeogenesis), to prevent hypoglycemia. Upon feeding, the liver reduces blood glucose levels via consumption (glycolysis) or via conversion of glucose to glycogen (glycogenesis) or triglyceride ifoxetine (lipogenesis). Genetically modified mice with defective mTOR signaling in the liver are glucose intolerant, hyperglycemic, hyperinsulinemic and display decreased glycogen content [44••, 48••, 68•, 69•• and 70••],

indicating that hepatic mTOR plays a major role in glucose homeostasis. Furthermore, the above defects are similar to those observed in patients with type 2 diabetes, suggesting that defective mTOR signaling in the liver accounts, at least partly, for the pathophysiology of type 2 diabetes. Lipogenesis is activated via the transcription factor sterol regulatory element-binding protein (SREBP) [71, 72 and 73]. As first demonstrated in retinal pigment epithelial cells and mouse embryonic fibroblasts (MEFs), mTORC1 mediates maturation of SREBP-1 in an S6K1-dependent manner to stimulate de novo lipid synthesis [ 74 and 75]. However, as shown in primary hepatocytes, mTORC1 stimulates SREBP-1 expression in an S6K-independent manner [ 76].